Background/ Aim: MicroRNAs (miRNAs) are known up-to-date candidate biomarkers for several diseases. In addition obtaining miRNA from different body fluids such as serum, plasma, saliva, and urine is relatively easy to handle. Herein we aimed to detect miRNAs as biomarkers for early stage prostate cancer (PC). For this purpose, we used urine and serum samples to detect any significant differences in miRNA profiles between patients and healthy controls. Total ribonucleic acid (RNA) in urine and serum samples were isolated from eight untreated PC patients and thirty healthy individuals were screened for miRNA profile and candidate miRNAs were validated. Whole urinary and serum miRNA profile was analyzed using Affymetrix GeneChip miRNA 4.0 Arrays. Candidate miRNAs were investigated by stem-loop reverse transcription - polymerase chain reaction. According to our results, when analyzed urinary samples of PC patients 49 miRNAs were detected up-regulated and 14 miRNAs were found down-regulated when compared with healthy controls. According to the serum samples 19 miRNAs were found up-regulated and 21 miRNAs were found down-regulated when compared with healthy individuals as well. Interestingly we detected overlapped only four miRNAs (MIR320A, MIR4535, MIR4706, MIR6750) that commonly increase or decrease in both serum and urine samples. Among them MIR320A was found down-regulated, and MIR4535, MIR4706, MIR6750 were found up-regulated fo urine samples. However only MIR6750 was up-regulated and the other three miRNAs were down-regulated for serum samples. Notably, the expression profile of MIR320A was significantly altered in urine specimens of prostate cancer patients. We considered that MIR320A has been evaluated as a valuable biomarker that can be used in the early diagnosis of the PC.